Join
Live feed
·
PRReleasevia Quantisnow
AEON Biopharma Inc. logo

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

ByQuantisnow·Wall Street's wire, on your screen.
AEON· AEON Biopharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AEON (AEON Biopharma Inc.) and more on Quantisnow.